Recessive COL4A2 mutation leads to intellectual disability, epilepsy, and spastic cerebral palsy

Somayeh Bakhtiari  
*Phoenix Children's Hospital*

Abbas Tafakhori  
*Tehran University of Medical Sciences*

Sheng Chih Jin  
*Washington University School of Medicine in St. Louis*

Brandon S. Guida  
*Phoenix Children's Hospital*

Elham Alehabib  
*Shahid Beheshti University*

*See next page for additional authors*

Follow this and additional works at: <https://digitalcommons.wustl.edu/open_access_pubs>

Please let us know how this document benefits you.

**Recommended Citation**

Bakhtiari, Somayeh; Tafakhori, Abbas; Jin, Sheng Chih; Guida, Brandon S.; Alehabib, Elham; Firouzabadi, Saghar; Bilguvar, Kaya; Fahey, Michael C.; Darvish, Hossein; and Krue, Michael C., "Recessive COL4A2 mutation leads to intellectual disability, epilepsy, and spastic cerebral palsy." Neurology Genetics. 7, 3. e583 (2021).  
https://digitalcommons.wustl.edu/open_access_pubs/10334
Authors
Somayeh Bakhtiari, Abbas Tafakhori, Sheng Chih Jin, Brandon S. Guida, Elham Alehabib, Saghar Firouzabadi, Kaya Bilguvar, Michael C. Fahey, Hossein Darvish, and Michael C. Krue
Recessive COL4A2 Mutation Leads to Intellectual Disability, Epilepsy, and Spastic Cerebral Palsy

Somayeh Bakhtiari, PhD, Abbas Tafakhori, MD, Sheng Chih Jin, PhD, Elham Alehabib, PhD, Saghar Firouzbadi, PhD, Kaya Bilguvar, MD, Michael C. Fahey, PhD, Hossein Darvish, PhD,* and Michael C. Kruer, MD*

Neurol Genet 2021;7:e583. doi:10.1212/NXG.0000000000000583

Dominant negative or haploinsufficient mutations in the collagen genes COL4A1 and COL4A2 are characterized by arterial basement membrane thickening resulting in a multisystem microangiopathy targeting the CNS but also potentially affecting the ocular, renal, cardiac, and muscular systems. Within the brain, such changes predispose affected individuals to recurrent ischemic and/or hemorrhagic strokes beginning during early fetal development but extending into the postnatal period and even into adulthood. Mutations affecting glycine residues of the Gly-Xaa-Yaw (typically representing glycine-proline-4-trans-hydroxyproline in vertebrates) repeat domains that typify collagens usually manifest in an autosomal dominant (AD) fashion. However, recent work suggests that tissue-specific mutation effects may also occur, with mutations leading to gain of function effects in some tissues and loss of function effects in others. Stroke-related complications may be insidious and clinically silent. Neuroimaging phenotypes of COL4A-associated disease include chronic white matter disease, porencephaly/hydranencephaly, encephalomalacia, cerebral calcifications, schizencephaly and hydrocephalus and corresponding clinical diagnoses of cerebral palsy, intellectual disability, cortical visual impairment, and epilepsy.

Type IV collagen α chains form heterotrimers with β chains in a 2:1 ratio, and incompletely penetrant AD inheritance is typical. Although autosomal recessive mutations of COL4A1 have been described, prior reports of COL4A2-associated disease have all featured AD inheritance. We describe 2 children from a consanguineous Iranian family with intellectual disability, spastic cerebral palsy, and epilepsy who each harbored the same homozygous mutation in COL4A2.

Pregnancies for both children were uncomplicated, and both were born at term by vaginal delivery. The couple’s 8 year-old son was bedridden and exhibited cortical visual impairment. He did not fix or track stimuli. He had never been able to sit unassisted or control his head. He did not speak or demonstrate communicative intent. He had focal epilepsy that began at age 6 months, partially controlled with carbamazepine. Motor examination revealed spastic quadriplegia with ophthalmoplegia, nystagmus, and skew deviation. Brain MRI revealed bilateral colpocephaly and irregular ventricular contours. His sister was 20 years old at the time of evaluation. Milestone attainment had been globally delayed. She also had focal epilepsy with onset at 18 months. Seizures were controlled with phenobarbital and carbamazepine. She began walking independently at age 3 years. At the time of evaluation, she did not speak, and her

*Both authors jointly supervised this work.

From the Pediatric Movement Disorders Program (S.B., B.S.G., M.C.K.), Barrow Neurological Institute, Phoenix Children’s Hospital, AZ; Departments of Child Health (S.B., B.S.G., M.C.K.), Neurology, Genetics, and Cellular & Molecular Medicine, University of Arizona College of Medicine Phoenix, Phoenix, AZ; Iranian Center of Neurological Research (A.T., H.D.), Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran; Department of Genetics (S.C.), Washington University School of Medicine, St. Louis, MO; Student Research Committee (E.A.), School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Genetics Research Center (S.F.), University of Social Welfare and Rehabilitation Sciences, Tehran, Iran; Department of Genetics (K.B.), Yale University, New Haven, CT; and Department of Paediatrics (M.C.F.), Monash University, Melbourne, Victoria, Australia.

Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by NIH 1R01NS106298.

gnomAD: gnomad.broadinstitute.org/
GME Variome server: igm.ucsd.edu/gme/

Corresponding author Michael Kruer takes responsibility for the accuracy of the data presented, the conduct of the research, providing access to the original data, and the right to publish.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
examination was significant for asymmetric spastic-dystonic quadriparesis with right-sided predominance. Her brain MRI showed irregular lateral ventricle contour with coalescent porencephaly and generalized cortical atrophy (figure, A). Neither patient was known to have ocular, kidney, skeletal, or cardiac muscle disease.

Both affected children and their parents provided informed consent for study participation in accordance with local ethics oversight and underwent whole-exome sequencing with filtering and variant prioritization as described previously. This revealed a homozygous c.3472G>C (p.G1158R) variant in COL4A2 (NM_001846) segregating with disease status in the family (both parents are neurologically healthy, although neuroimaging was not able to be performed) (figure, B). This variant is novel (not found in gnomAD or the Greater Middle Eastern Variome server) and predicted to be deleterious (MetaSVM, CADD, SIFT, and PolyPhen), putatively by disrupting a glycine residue within a highly conserved Gly-Xaa-Yaw collagen triple helix repeat domain. Such glycine residues are known to be critical determinants of collagen stability and we anticipate that the substitution of an arginine residue to have a destabilizing effect.6

In comparison to previously described incompletely penetrant dominantly inherited mutations in COL4A2, this homozygous (p.G1158R) variant appears to exhibit autosomal recessive inheritance, although our observations will benefit from subsequent confirmation. Our results indicate that both dominant and recessive forms of COL4A2 disease exist. This finding has potentially important implications for the interpretation of clinical genetic testing in cases of porencephaly, hydrocephalus or idiopathic antenatal or perinatal ischemic/hemorrhagic stroke and for associated clinical phenotypes including epilepsy, intellectual disability, and cerebral palsy.7

Data Availability
Full data are available to qualified investigators on reasonable request to the corresponding author.

Acknowledgment
The authors thank the patients and their family members for their support of this work.

Study Funding
NIH; 1R01 NS106298.

Disclosure
MCK serves as a consultant for PTC Therapeutics and the United States National Health Services Administration and has performed grant review for the United States Department of Defense. The remaining authors report no disclosures.
related to the conduct of this manuscript. Bioinformatic and statistical analysis performed by SB and SCJ. Go to Neurology.org/NG for full disclosures.

**Publication History**
Received by *Neurology: Genetics* September 21, 2020. Accepted in final form February 15, 2021.

**Appendix**

### Authors

| Name                  | Location                                      | Contribution                                                                 |
|-----------------------|-----------------------------------------------|-----------------------------------------------------------------------------|
| Somayeh Bakhtiari, PhD| Phoenix Children’s Hospital                   | Designed and conducted bioinformatic analysis and revised the manuscript for important intellectual content |
| Abbas Tafakhori, MD   | Tehran University of Medical Sciences          | Enrolled participants; performed clinical phenotyping; and revised the manuscript for important intellectual content |
| Sheng Chih Jin, PhD   | Washington University, St. Louis              | Designed bioinformatic analysis and revised the manuscript for important intellectual content |
| Brandon S. Guida, PhD | Phoenix Children’s Hospital                   | Designed and conceptualized the study and revised the manuscript for important intellectual content |
| Elham Alehabib, PhD   | Shahid Beheshti University of Medical Sciences | Enrolled participants; performed clinical phenotyping; and revised the manuscript for important intellectual content |
| Saghar Firoozabadi, PhD| University of Social Welfare and Rehabilitation Sciences, Tehran | Enrolled participants; performed clinical phenotyping; and revised the manuscript for important intellectual content |
| Kaya Bilguvar, MD     | Yale University                                | Designed and conceptualized the study and revised the manuscript for important intellectual content |
| Michael C. Fahey, PhD | Monash University                              | Designed and conceptualized the study and revised the manuscript for important intellectual content |
| Hossein Darvish, PhD  | Tehran University of Medical Sciences          | Designed and conceptualized the study; integrated clinical and genomic findings; and revised the manuscript for important intellectual content |
| Michael C. Kruer, MD  | Phoenix Children’s Hospital                   | Designed and conceptualized the study; integrated clinical and genomic findings; and drafted and revised the manuscript |

**Appendix (continued)**

### References

1. van der Knaap MS, Smit LM, Barkhof F, et al. Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. *Ann Neurol* 2006;59(3):504-511.
2. Labelle-Dumais C, Schuitema V, Hayashi G, et al. *COL4A1* mutations cause neuromuscular disease with tissue-specific mechanistic heterogeneity. *Am J Hum Genet* 2019;104(5):847-860.
3. Zagaglia S, Selch C, Nisevic JR, et al. Neurologic phenotypes associated with COFL4A1/2 mutations: expanding the spectrum of disease. *Neurology* 2018;91(22):e2078-e2088.
4. Yaramis A, Lochm¨uller H, T¨opf A, et al. *COL4A1*-related autosomal recessive encephalopathy in 2 Turkish children. *Neurol Genet* 2020;6(1):e392.
5. Jin SC, Lewis SA, Bakhtiari S, et al. Mutations disrupting neurotogenesis genes confer risk for cerebral palsy. *Dev Med Child Neurol* 2017;59(5):462-469.
Recessive COL4A2 Mutation Leads to Intellectual Disability, Epilepsy, and Spastic Cerebral Palsy
Somayeh Bakhtiari, Abbas Tafakhori, Sheng Chih Jin, et al.

Neurol Genet 2021;7;
DOI 10.1212/NXG.0000000000000583

This information is current as of April 26, 2021
